Rayonier (NYSE:RYN – Get Free Report) and National Health Investors (NYSE:NHI – Get Free Report) are both mid-cap construction companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, dividends, institutional ownership and profitability.
Earnings & Valuation
This table compares Rayonier and National Health Investors”s revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Rayonier | $1.06 billion | 4.44 | $173.49 million | $1.00 | 31.47 |
National Health Investors | $319.83 million | 10.43 | $135.65 million | $2.94 | 26.11 |
Rayonier has higher revenue and earnings than National Health Investors. National Health Investors is trading at a lower price-to-earnings ratio than Rayonier, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Rayonier | 0 | 2 | 0 | 0 | 2.00 |
National Health Investors | 0 | 3 | 4 | 0 | 2.57 |
Rayonier presently has a consensus price target of $33.00, suggesting a potential upside of 4.86%. National Health Investors has a consensus price target of $73.29, suggesting a potential downside of 4.53%. Given Rayonier’s higher possible upside, analysts plainly believe Rayonier is more favorable than National Health Investors.
Volatility and Risk
Rayonier has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. Comparatively, National Health Investors has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500.
Institutional & Insider Ownership
89.1% of Rayonier shares are owned by institutional investors. Comparatively, 62.5% of National Health Investors shares are owned by institutional investors. 0.8% of Rayonier shares are owned by insiders. Comparatively, 8.2% of National Health Investors shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Dividends
Rayonier pays an annual dividend of $1.14 per share and has a dividend yield of 3.6%. National Health Investors pays an annual dividend of $3.60 per share and has a dividend yield of 4.7%. Rayonier pays out 114.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. National Health Investors pays out 122.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
Profitability
This table compares Rayonier and National Health Investors’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Rayonier | 14.78% | 3.00% | 1.53% |
National Health Investors | 39.11% | 10.11% | 5.13% |
Summary
National Health Investors beats Rayonier on 9 of the 15 factors compared between the two stocks.
About Rayonier
Rayonier is a leading timberland real estate investment trust with assets located in some of the most productive softwood timber growing regions in the United States and New Zealand. As of December 31, 2023, Rayonier owned or leased under long-term agreements approximately 2.7 million acres of timberlands located in the U.S. South (1.85 million acres), U.S. Pacific Northwest (418,000 acres) and New Zealand (421,000 acres).
About National Health Investors
Incorporated in 1991, National Health Investors, Inc. (NYSE:NHI) is a real estate investment trust specializing in sale, leasebacks, joint-ventures, senior housing operating partnerships, and mortgage and mezzanine financing of need-driven and discretionary senior housing and medical investments. NHI's portfolio consists of independent living, assisted living and memory care communities, entrance-fee retirement communities, skilled nursing facilities, and specialty hospitals.
Receive News & Ratings for Rayonier Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rayonier and related companies with MarketBeat.com's FREE daily email newsletter.